AI-Pharma is a hybrid investment fund specifically focused on the AI in Pharma and Drug Discovery sector, backed by seasoned professionals who have been active in both the investment banking and AI for Drug Discovery industries for years, long before the sector was recognized as a serious prospect by the overwhelming majority of investors, and some of whom made their first investments into the sector in 2014. The fund structures its portfolio based on sophisticated industry intelligence and comparative analytics provided by the Pharma Division of Deep Knowledge Analytics, the world-leading source of market intelligence on the AI for Drug Discovery, Biomarker Discovery and Advanced R&D sector, and which uses hundreds of quantitative and fact-based parameters to identify prospective investment targets for the fund, utilizing multidimensional analytical frameworks as complex as the industry itself.
AI for Drug Discovery, Biomarker Development and Advanced R&D is considered by the majority of experts and analysts as one of the most prospective sectors in the Pharma industry, with the greatest disruptive potential and capability to increase the efficiency and decrease the cost of developing new drugs, and to improve the performance and profitability of leading Pharma corporations.
Provides Liquidity Similar to Hedge Funds Combined With Venture Fund Style Objectives
Invests in the Top 10% of Companies in the Longevity Industry
Significantly De-Risks the Interests of Limited Partners and Portfolio
Bets on the Success of the Entire Industry, rather than of Individual Companies